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BACKGROUND: Arrhythmogenic cardiomyopathy/arrhythmogenic 
right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease 
characterized by fibrofatty replacement of the myocardium, resulting 
in heart failure and sudden cardiac death. The most aggressive 
arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), 
caused by a p.S358L mutation in TMEM43 (transmembrane protein 
43). The function and localization of TMEM43 are unknown, as is the 
mechanism by which the p.S358L mutation causes the disease. Here, 
we report the characterization of the first transgenic mouse model of 
ARVC5.
METHODS: We generated transgenic mice overexpressing TMEM43 in 
either its wild-type or p.S358L mutant (TMEM43-S358L) form in postnatal 
cardiomyocytes under the control of the α-myosin heavy chain promoter.
RESULTS: We found that mice expressing TMEM43-S358L recapitulate 
the human disease and die at a young age. Mutant TMEM43 causes 
cardiomyocyte death and severe fibrofatty replacement. We also 
demonstrate that TMEM43 localizes at the nuclear membrane and 
interacts with emerin and β-actin. TMEM43-S358L shows partial 
delocalization to the cytoplasm, reduced interaction with emerin 
and β-actin, and activation of glycogen synthase kinase-3β (GSK3β). 
Furthermore, we show that targeting cardiac fibrosis has no beneficial 
effect, whereas overexpression of the calcineurin splice variant 
calcineurin Aβ1 results in GSK3β inhibition and improved cardiac 
function and survival. Similarly, treatment of TMEM43 mutant mice 
with a GSK3β inhibitor improves cardiac function. Finally, human 
induced pluripotent stem cells bearing the p.S358L mutation also 
showed contractile dysfunction that was partially restored after GSK3β 
inhibition.
CONCLUSIONS: Our data provide evidence that TMEM43-S358L 
leads to sustained cardiomyocyte death and fibrofatty replacement. 
Overexpression of calcineurin Aβ1 in TMEM43 mutant mice or chemical 
GSK3β inhibition improves cardiac function and increases mice life span. 
Our results pave the way toward new therapeutic approaches for ARVC5.
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Arrhythmogenic cardiomyopathy (ACM)/ar-rhythmogenic right ventricular cardiomyopa-thy (ARVC) is an incurable genetically inherited 
disease that causes heart failure and sudden cardiac 
death.1,2 ACM/ARVC is an autosomal dominant dis-
ease with rare recessive forms. To date, 15 indepen-
dent loci and 13 dominant ACM/ARVC–causing genes 
have been linked to the condition. Up to 60% of ACM/
ARVC cases have been attributed to mutations in genes 
encoding proteins of the desmosomal complex, with a 
significant minority caused by mutations in nondesmo-
somal genes.3–5 The most aggressive ACM/ARVC sub-
type is ACM/ARVC type 5 (ARVC5), which is caused 
by a point substitution (p.S358L) in a highly conserved 
TMEM43/LUMA (transmembrane region of transmem-
brane protein 43). The causal gene for ARVC5 was first 
described in families from Newfoundland (Canada) in 
2008 as the cause of a fully penetrant aggressive dis-
ease with a high incidence of malignant ventricular 
arrhythmias.6 Since then, several other patients have 
been diagnosed around the globe. Prognosis is very 
poor, with more than half of affected men dying by the 
age of 50 years.7 The pathogenic mechanism of ARVC5 
and the role of TMEM43 in the genesis of the disease 
are poorly understood, precluding the development of 
effective therapies.
Here, we report the characterization of the first trans-
genic mouse model of ARVC5. We analyzed disease de-
velopment and progression in depth and determined 
the localization, function, and mechanism of action 
of TMEM43. Finally, we show that glycogen synthase 
kinase-3β (GSK3β) inhibition with a chemical inhibitor 
or by calcineurin Aβ1 (CnAβ1) overexpression improves 
cardiac function and survival of mice with ARVC5.
METHODS
Data Availability
The data that support the findings of this study are avail-
able from the corresponding authors on reasonable 
request. RNA sequencing data are available at the GEO 
repository (GSE101301). Proteomic data are available at the 
PeptideAtlas repository (http://www.peptideatlas.org/PASS/
PASS01063). Full Methods can be found in the online-only 
Data Supplement.
Mice
TMEM43 wild-type (TMEM43WT) and TMEM43 mutant 
(TMEM43mut) mice, in the C57BL/6JCrl (Charles River 
Laboratories) background, express human WT TMEM43 
and human TMEM43-S358L, respectively, specifically in 
cardiomyocytes under the control of the myosin heavy 
chain (MHC)  promoter.  WT  C57BL/6JCrl mice were used 
as controls. TMEM43mut male mice were  crossed with α-
myosin heavy chain–CnAβ1 mice8 to generate the double-
transgenic mouse line TMEM43mut-CnAβ1. Male and 
female mice were used throughout the study. Mice were 
housed in an air-conditioned room with a 12-hour light/
dark cycle with free access to water and chow. For the inhi-
bition of galectin 3, TMEM43mut mice were randomized 
to the saline-treated control group (n=8) or the GM-CT-
01–treated group (n=8). Mice were treated twice a week 
with intravenous injections of GM-CT-01 (120 mg/kg) or 
placebo (normal saline) in the tail vein from 5 weeks to 4 
months of age. For GSK3β inhibition, mice were injected 
intraperitoneally daily with SB216763 (2.5 mg/kg per day). 
All procedures were approved by the Centro Nacional de 
Investigaciones Cardiovasculares Carlos III Ethics Committee 
and the Regional Government of Madrid (PA-27/13, PROEX-
177/17). All animal experiments conformed to EU Directive 
2010/63EU and Recommendation 2007/526/EC, enforced in 
Spanish law under Real Decreto 53/2013.
Echocardiography
Cardiac function, chamber dilatation, and wall thickness were 
analyzed in neonatal mice and in mice 3 and 5 weeks and 2 
and 4 months of age by transthoracic 2D and M-mode echocar-
diography. Measurements were carried out by a blinded opera-
tor using a high-frequency ultrasound system with a 50-MHz 
linear probe for neonates and a 30-MHz probe for older mice 
(Vevo 2100, Visualsonics Inc). For ultrasound scans, mice were 
Clinical Perspective
What Is New?
• This is the first animal model to reproduce human 
arrhythmogenic right ventricular cardiomyopathy 
(ARVC) type 5, the most aggressive subtype of 
arrhythmogenic cardiomyopathy.
• Transgenic mice expressing TMEM43 (transmem-
brane protein 43)–S358L show fibrofatty replace-
ment of the myocardium and die at a young age.
• This model confirms that TMEM43 is localized 
mostly at the nuclear membrane and provides new 
information on the pathophysiological mechanism 
of ARVC5.
• As in other forms of ARVC, the glycogen synthase 
kinase-3β signaling pathway plays an important 
role in this disease.
What Are the Clinical Implications?
• Using this animal model, our work tests 2 new 
therapeutic approaches for ARVC5, for which 
there are currently no effective therapies to prevent 
disease progression in humans.
• Although the antifibrotic drug GM-CT-01 did 
not show a beneficial effect on transgenic mice 
expressing TMEM43-S358L, inhibition of glycogen 
synthase kinase-3β improved cardiac function and 
survival, opening the way to a new therapeutic 
approach focused on glycogen synthase kinase-
3β inhibition that could be used in humans with 
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placed on a heating pad; neonates were not anesthetized, 
whereas older mice were kept under light anesthesia with iso-
flurane adjusted to obtain a target heart rate of 500±50 bpm. 
Left ventricular (LV) ejection fraction (EF) and LV end-diastolic 
volume were obtained from the long-axis view, and LV pos-
terior wall in diastole was obtained from the short-axis view. 
Right ventricular systolic function was assessed indirectly from 
the tricuspid annular plane systolic excursion, estimated from 
maximum lateral tricuspid annulus movement obtained from 
a 2D 4-chamber apical view. Images were analyzed offline by 
an expert using the Vevo 2100 Workstation software. Animals 
were euthanized by gradually filling the chamber with carbon 
dioxide. Mice, hearts, and lungs were weighed after death.
Electrocardiograms
ECGs were obtained in unanesthetized neonates and in 
3- and 5-week-old and 2- and 4-month-old anesthetized 
mice with bipolar limb leads (leads I, II, and III) and unipolar 
limb leads (leads aVR, aVL, and aVF) for 60 to 90 seconds. 
Measurements were taken by a blinded operator with mice 
(except for neonates) placed under light anesthesia with iso-
flurane (MP36R, BIOPAC Systems, Inc). ECGs were analyzed 
by an expert using Acqknowledge 4.1.1. for MP36R (BIOPAC 
Systems, Inc). Mean values were calculated from 10 consecu-
tive standard ECG time intervals and waves.
Cell Culture, Transfection, and 
Immunofluorescence
P19 cells were transfected with the following HA-tagged 
expression vectors for TMEM43: TMEM43WT-Ct-HA, Nt-HA-
TMEM43WT, TMEM43-S358L-Ct-HA, and Nt-HA-TMEM43-
S358L, where Nt and Ct indicate attachment of the HA tag 
to the N-terminus or the C-terminus. Cells were fixed in 4% 
paraformaldehyde in PBS for 10 minutes at 4°C, permeabilized 
for 10 minutes with 0.1% Triton X-100/PBS, and incubated in 
10% goat serum/PBS for 30 minutes at room temperature. Cells 
were incubated overnight in 1% goat serum/PBS with anti-HA 
(11583816001, Roche). After primary antibody incubation, cells 
were washed with PBS, incubated for 1 hour at room tempera-
ture with Alexa Fluor 488 goat anti-mouse immunoglobulin G 
(A-11029; Thermo Fisher Scientific) and DAPI in 1% goat serum/
PBS, and mounted in Vectashield mounting medium. Images 
were acquired with a Nikon A1R multiline inverted confocal 
microscope, a Plan Apo VC 60×/1,4 Oil DIC N2 Oil objective, 
and Nikon NIS reprocessing software. Brightness and contrast 
were linearly adjusted with Adobe Photoshop CS5.1.
Immunoprecipitation
TMEM43 immunoprecipitation experiments were performed 
in the P19 cell line. Briefly, cells were transfected as described 
above. Cells were lysed with TBS buffer (150 mmol/L NaCl, 
20 mmol/L Tris-HCl, pH 7.4) supplemented with 1% Nonidet 
P-40, 5 mmol/L EDTA, 5 mmol/L MgCl2, and 1× complete pro-
tease, phosphatase, and acetylase inhibitors. Protein extracts 
were incubated with anti-HA–conjugated Dynabeads (Life 
Technologies) for 1 hour at 4°C. Beads were washed 3 times 
with lysis buffer containing 0.05% Nonidet P-40 and 5 times 
with lysis buffer without added detergent. Bound proteins 
were released from beads by boiling in 4× Laemmli sample 
buffer. Immunoprecipitates and input samples were resolved by 
SDS-PAGE or subjected to protein digestion followed by nano-
liquid chromatography coupled to mass spectrometry for pro-
tein identification and quantification by peptide counting.9 The 
proteomics data set (raw and msf files and protein database) 
is available in the PeptideAtlas repository (http://www.peptid-
eatlas.org/PASS/PASS01063, which can be downloaded via ftp.
peptideatlas.org: username, PASS01063; password, FZ6532b).
Statistical Analysis
All data are presented as mean±SEM. All data sets were 
analyzed for statistical significance by regular or repeated-
measures 1-way ANOVA followed by Bonferroni or Dunnett 
posttest for multiple comparisons or 2-way ANOVA followed 
by Bonferroni posttest (GraphPad Prism), as indicated in the 
figure legends. Survival curves were compared by the log-
rank (Mantel-Cox) test. Differences were considered statisti-
cally significant at P<0.05.
RESULTS
Cardiac-Restricted Expression of Human 
TMEM43-S358L Induces Biventricular 
Dysfunction and Reduces Survival
We generated transgenic mice expressing human 
TMEM43-S358L under the control of the α-myosin 
heavy chain promoter (TMEM43mut mice) to pro-
vide cardiac-specific expression of the mutant protein. 
As controls, we used mice overexpressing human WT 
TMEM43 (TMEM43WT mice) and WT littermates (Figure 
IA–IC in the online-only Data Supplement). TMEM43mut 
mice were dead by 6 months of age, with a median life 
span of 23 weeks, whereas TMEM43WT and WT mice 
showed no notable mortality at this age (Figure 1A).
Echocardiography showed a decline in LVEF that was 
already evident in the TMEM43mut group at 2 months 
of age, indicating a loss of LV contractility (Figure 1B 
and Table I and Video I in the online-only Data Supple-
ment). Accordingly, TMEM43mut mice also developed 
progressive LV dilatation with a high LV end-diastolic 
volume (Figure 1C). Right ventricular contractility was 
also reduced in TMEM43mut mice at 4 months of age 
(Figure 1D). Although death was slightly delayed in fe-
males, no significant differences in survival and cardiac 
function were observed between males and females 
(Figure ID–IF in the online-only Data Supplement).
Gross morphology at 4 months revealed a clear en-
largement of TMEM43mut hearts compared with TMEM-
43WT and WT hearts (Figure 1E). TMEM43mut mice also 
had an elevated ratio of heart weight to body weight at 4 
months (Figure 1F). However, no changes were observed 
in ventricular wall thickness (Figure 1G). Decreased car-
diac function in TMEM43mut mice was accompanied by 
pulmonary congestion at 4 months (Figure 1H).
Electrocardiographic analysis showed progressive P-
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atria in TMEM43mut mice, some of which developed 
atrial fibrillation and atrial paralysis (Figure 2A and 2D 
and Table II in the online-only Data Supplement). Simi-
larly, TMEM43mut mice had ventricular disease, as evi-
denced by a progressive widening of the QRS complex 
(Figure 2B and 2E) and a progressive decrease in QRS 
amplitude (Figure 2C and 2F). No differences were ob-
served between males and females (Figure II in the on-
line-only Data Supplement). Together, the results of the 
ECG suggest that TMEM43mut mice develop electric 
defects already noticeable at 5 weeks of age.
TMEM43-S358L Expression in the Heart 
Induces Cardiomyocyte Death and 
Fibrofatty Replacement
An important hallmark of human ACM/ARVC is the 
progressive fibrofatty replacement of the ventricular 
myocardium10; however, whether fibrofatty replace-
ment is preceded by cardiomyocyte death has not been 
clearly demonstrated. We found a significant increase 
in circulating cardiac troponin I levels in TMEM43mut 
mice as early as 5 weeks of age (Figure 3A), indicating 
Figure 1. TMEM43 (transmembrane protein 43)–S358L expression in cardiomyocytes causes severe cardiac dysfunction.  
A, Wild-type mice (WT; n=27) and mice overexpressing either WT TMEM43 (TMEM43WT; n=29) or TMEM43-S358L (TMEM43mut; n=84) under the control of the 
α-myosin heavy chain (αMHC) promoter were monitored for 60 weeks, and their survival rate was determined from a Kaplan-Meier curve. The indicated P value 
was obtained with a log-rank test. B through D, Left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), and tricuspid annular plane systolic excur-
sion (TAPSE) measured by echocardiography at birth (Neon) and at 3 and 5 weeks and 2 and 4 months of age. E, Gross morphology of representative hearts from 
4-month-old WT, TMEM43WT, and TMEM43mut mice; bar, 500 μm. Inset, A thrombus in the left atrium of a TMEM43mut mouse; bar, 50 μm. F, Ratio of heart 
weight to body weight (HW/BW) determined at birth and at 4 months. G, LV posterior wall thickness in diastole (LVPWd) analyzed by echocardiography. H, Ratio 
of lung weight to body weight (LW/BW) determined at birth and at 4 months. Graphs show mean±SEM. **P<0.01, ***P<0.001, TMEM43mut vs WT. #P<0.05, 
##P<0.01, ###P<0.001, TMEM43mut vs TMEM43WT. $P<0.05, $$P<0.01, $$$P<0.001 for different time points vs neonates (B, C, and G) or 3 weeks (D) for each 
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cardiomyocyte necrosis. We also investigated the acti-
vation of apoptosis by assessing the presence of pro-
caspase 3 and cleaved caspase 3 in the hearts of these 
mice. At 2 months of age, TMEM43mut mice showed 
increased levels of cleaved caspase 3, which were main-
tained at 4 months, although the differences did not 
reach statistical significance (Figure 3B and Figure IIIA in 
the online-only Data Supplement). In addition, a similar 
Figure 2. TMEM43 (transmembrane protein 43) mutant (mut) mice show cardiac conduction defects.  
A through C, Surface electrocardiographic analysis of cardiac conduction in wild-type (WT), TMEM43WT, and TMEM43mut mice 1 day (A), 5 weeks (B), and 4 
months (C) of age. Shown are 0.6-second traces from the V3 lead. D through F, The p-wave duration (D) and QRS duration and amplitude (E and F) assessed at 
birth (Neon) and at 3 and 5 weeks and 2 and 4 months of age. Graphs show mean±SEM. **P<0.01, ***P<0.001, TMEM43mut vs WT. ###P<0.001, TMEM43mut 
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trend was found for Beclin1, a key protein involved in 
autophagy11 (Figure 3C and Figure IIIB in the online-only 
Data Supplement). These results provide the first clear 
evidence implicating cell-death pathways in the early 
and sustained cardiomyocyte loss in ARVC5.
To determine whether dead cardiomyocytes were 
substituted by fibrotic tissue, we analyzed heart sec-
tions by Masson trichrome staining. TMEM43mut mice 
showed massive fibrosis in both ventricles at 4 months 
of age (Figure 3D–3G). Mutant mice also showed accu-
mulation of adipose tissue in the subepicardial layer and 
the myocardium, as revealed by perilipin staining (Fig-
ure 3H). Quantification of the fibrotic area confirmed 
the strong fibrotic response as disease progressed (Fig-
ure  3I). In line with these results, TMEM43mut mice 
showed an increase in collagen 1α1 mRNA at 2 and 
4 months, together with strong induction of lysyl oxi-
dase, which crosslinks collagen and elastin (Figure IIIC 
and IIID in the online-only Data Supplement). These 
changes were accompanied by increased expression of 
the myocardial remodeling markers skeletal muscle ac-
tin α1 and brain natriuretic peptide (Figure IIIE and IIIF 
in the online-only Data Supplement). Together, these 
results demonstrate that TMEM43-S358L induces car-
diomyocyte death followed by fibrotic replacement.
Epicardium-Derived Cells Contribute 
to the Fibrotic Replacement of 
Cardiomyocytes
Using the Cre-LoxP technology and cell type–specific 
promoters, we generated 4 sets of lineage-tracing 
mice to determine the contribution made to the fi-
brotic replacement by endothelial cells (Tie2-Cre), mac-
Figure 3. TMEM43 (transmembrane protein 43)–S358L causes cardiomyocyte death and replacement by fibrofatty tissue.  
A, Serum troponin I (TnI) determined by ELISA in mice 3 and 5 weeks and 2, 3, and 4 months of age. B and C, Western blot analysis of the presence in myocar-
dium of activated and total caspase 3 (casp-3; B) and beclin1 (Becl; C) at the indicated time points. D through I, Masson trichrome staining in myocardial sections 
from wild-type (WT; D), TMEM43WT (E), and TMEM43 mutant (mut) mice (F and G). Subepicardial adipocytes were stained with perilipin (H), and the percentage 
of fibrotic tissue was quantified (I). Bar, 500 μm (D–F), 50 μm (G), and 100 μm (H). Graphs show data points for individual mice and mean±SEM. Vinc indicates 
vinculin. A and I, **P<0.01, ***P<0.001, TMEM43mut vs WT; #P<0.05, ##P<0.01, ###P<0.001, TMEM43mut vs TMEM43WT; $P<0.05, $$P<0.01, $$$P<0.001 
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rophages (LysM-Cre), cardiomyocytes (cTnT-Cre), and 
epicardium-derived cells (Wt1-Cre). In addition to the 
TMEM43mut transgene, each line carried a floxed re-
porter allele (EYFP, RFP, or GFP) preceded by a STOP 
codon that was removed on recombination by the Cre 
recombinase. In these mice, Cre-expressing cells and 
their progeny were permanently labeled by expression 
of the reporter (Figure IVA–IVQ in the online-only Data 
Supplement). To locate collagen fibers in myocardial tis-
sue, we used second-harmonic-generation microscopy 
(Figure IVA in the online-only Data Supplement), which 
highlights organized mature collagen fibers, and confo-
cal reflection microscopy (Figure IVB in the online-only 
Data Supplement), which reveals general tissue fibrosis. 
Labeled macrophages were found in the tissue but did 
not colocalize with the collagen fibers (Figure IVC–IVE 
in the online-only Data Supplement), and neither did 
the cardiomyocytes or endothelial cells (Figure IVF–IVH 
and IVO–IVQ in the online-only Data Supplement). In 
contrast, both second-harmonic-generation and reflec-
tion microscopy revealed colocalization of epicardium-
derived cells and collagen fibers in TMEM43mut hearts 
(Figure IVI–IVN in the online-only Data Supplement). 
These results indicate that epicardium-derived cells 
(which are likely resident fibroblasts derived from the 
epicardium during development) are the main cell type 
contributing to the massive interstitial fibrosis observed 
in ARVC5.
TMEM43 Is Located in the Nuclear 
Membrane and Interacts With 
Cytoskeleton-Binding Proteins
There is currently controversy about whether TMEM43 is 
located within the nuclear rim,12 the endoplasmic reticu-
lum,13 or the intercalated disk.14 To investigate the cel-
lular localization of WT and S358L human TMEM43 and 
their interacting partners, we first modeled TMEM43-
S358L and WT TMEM43 proteins in silico. The p.S358L 
mutation in transmembrane domain 3 (red in Figure 4A 
and 4B) predicted disruption of 3D protein structure 
and lower structural stability for TMEM43-S358L com-
pared with WT TMEM43. TMEM43-S358L also showed 
higher hydrophobicity than the WT form, reducing the 
availability of the transmembrane domain 4 (dark blue 
in Figure 4A and 4B), which is predicted to interact with 
a partner protein. The p.S358L mutation also affected 
the structure of the transmembrane domain 1 (orange 
in Figure 4A and 4B), which is necessary for TMEM43 
dimerization. Because a previous report suggested that 
TMEM43 function requires dimerization through trans-
membrane domain 1,15 we also modeled homodimers 
and heterodimers of TMEM43WT and TMEM43mut. 
In silico modeling of the heterodimer WT TMEM43-
TMEM43-S358L revealed a distorted structure compared 
with the WT TMEM43 homodimer (Figure 4C and 4D).
TMEM43 protein sequence is highly conserved along 
evolution.8 Nevertheless, the in silico model of mouse 
TMEM43 shows a different tertiary structure compared 
with the human protein, with a nonstructured loop ar-
ranging transmembrane domains 3 and 4 differently 
(Figure VA in the online-only Data Supplement). Most 
important, the p.S358L mutation has virtually no ef-
fect on the mouse TMEM43 structure, and mouse 
TMEM43-S358L shows only minimal differences with 
the WT protein (Figure VB and VC in the online-only 
Data Supplement). These results probably explain why 
TMEM43-S358L knock-in mice have no disease pheno-
type,16 whereas transgenic mice expressing the human 
protein develop ARVC5.
TMEM43 has been suggested to interact with emer-
in (Emery-Dreifuss muscular dystrophy [EMD]) and 
SUN2 (SUN domain-containing protein).15 We therefore 
modeled the interaction of these proteins with human 
TMEM43 dimers. The WT-mutant TMEM43 heterodimer 
showed an interaction with EMD (purple in Figure 4E); 
however, this interaction was predicted to abnormally 
embed EMD in the nuclear membrane (Figure 4F). This 
would have the effect of blocking EMD function be-
cause it would prevent its interaction with lamin A (the 
pocket in EMD that interacts with lamin A is indicated 
by an arrow in Figure 4E and 4F). This in silico predic-
tion was validated by immunoprecipitation in P19 cells 
transfected with expression plasmids for HA-tagged WT 
TMEM43 and TMEM43-S358L, which revealed weaker 
interaction of EMD with TMEM43-S358L than with the 
WT form (Figure  4G). These results suggest that the 
p.S358L point mutation in human TMEM43 results in 
a dominant-negative form of TMEM43, disrupting the 
activity of the WT form.
Histological analysis of hearts from 4-month-old mice 
using 3 different anti-TMEM43 antibodies showed peri-
nuclear localization of TMEM43 in TMEM43WT mice, 
whereas the TMEM43-S358L protein was partially de-
localized in the cytoplasm in TMEM43mut mice (Fig-
ure 4H–4M). As in desmoplakin ACM/ARVC and other 
ARVC models,17,18 TMEM43mut mouse hearts showed 
mislocalization of connexin 43 (Figure VI in the online-
only Data Supplement).
To validate those results, we analyzed TMEM43 local-
ization in P19 cells transfected with plasmids expressing 
HA-tagged TMEM43 proteins. We found partial cyto-
plasmic localization of TMEM43-S358L, regardless of 
whether the HA tag was placed at the N- or the C-ter-
minus, whereas the WT protein showed a mainly peri-
nuclear staining (Figure VII in the online-only Data Sup-
plement). The perinuclear localization of WT TMEM43 
in the nuclear membrane is in agreement with several 
previous reports.13,15,16,19–21 It should be acknowledged, 
however, that TMEM43 has also been reported in des-
mosomes.14 Although we could not detect TMEM43 in 
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Figure 4. The S358L mutation alters TMEM43 (transmembrane protein 43) conformation and protein interactions.  
A through F, In silico modeling of the tertiary structure of wild-type (WT; A, C, and E, light blue) and mutant (mut) TMEM43 (B, D, and F, green) as mono-
mers (A and B), dimers (C and D), or in complexes with emerin (EMD; purple molecule; E and F). Orange indicates transmembrane domain 1; red, transmem-
brane domain 3; dark blue, transmembrane domain 4; and black residue, S358L mutation. G, HA-tagged TMEM43WT and TMEM43mut were expressed 
in P19 cells and immunoprecipitated (IP) with anti-HA. The presence of TMEM43, EMD, and β-actin in the input and immunoprecipitate was analyzed by 
Western blot. H through M, Immunofluorescence analysis of TMEM43 localization in myocardial sections from 4-month-old TMEM43WT (H, J, and L) and 
TMEM43mut mice (I, K, and M) with 3 different anti-TMEM43 antibodies (H and I, Abcam; J and K, Santa Cruz; L and M, antibodies generated by Franke et 
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interaction with desmosomal proteins in immunopre-
cipitation experiments (Table III in the online-only Data 
Supplement), suggesting that a fraction of TMEM43 
may be localized in desmosomes.
To gain insight into the molecular partners of 
TMEM43, we immunoprecipitated the WT and the 
mutant protein from transfected P19 cells using an 
anti-HA antibody. Quantitative proteomics of the co-
precipitating proteins identified several cytoskeleton 
and cytoskeleton-interacting proteins among the 
binding partners for WT TMEM43, including actin, ac-
tinin, spectrin, shroom 3, myosin, and formin-like 2 
(Table III in the online-only Data Supplement). Many 
of these interactions were reduced in cells expressing 
TMEM43-S358L. Immunoprecipitation and Western 
blot analysis confirmed the reduced interaction of 
TMEM43-S358L with α-actin compared with the WT 
TMEM43 form (Figure 4G). Interestingly, the mutant 
TMEM43 protein showed increased interaction with 
the AKT modulator Pa2g4 (Table III in the online-only 
Data Supplement), which might affect this signaling 
pathway.
Antifibrotic Treatment Does Not Improve 
Cardiac Function in ARVC5 Mice
Increased interstitial fibrosis is a hallmark of human 
ARVC5 and was evident in TMEM43mut mice. Inter-
stitial fibrosis increases passive stiffness, causes elec-
tric remodeling, and enhances arrhythmogenicity, 
further contributing to cardiac remodeling and dys-
function.1,22 To investigate whether reducing intersti-
tial fibrosis could improve heart function in ARVC5, 
we treated mice with the β-galactoside–binding lectin 
Gal-3 (galectin-3) inhibitor GM-CT-01, a known anti-
fibrotic drug23.
Gal-3 is highly expressed in fibrotic tissues23 and me-
diates extracellular matrix remodeling in heart failure.24 
Gal-3–null mice are resistant to fibrotic disease of sev-
eral organs, including liver, kidney, and lung.25 RNA 
sequencing revealed increased expression of the Gal-
3-encoding gene (Lgals3) in the hearts of 2-month-old 
TMEM43mut mice, together with other genes involved 
in the immune response and fibrosis (Table IV and Fig-
ure VIII in the online-only Data Supplement). No major 
changes in transcript isoforms were detected (Table V in 
the online-only Data Supplement). Validation by quan-
titative reverse-transcribed polymerase chain reaction 
showed a strong induction of Lgals3 in TMEM43mut 
mice at 2 and 4 months of age (Figure  5A), which 
was confirmed by Western blot (Figure  5B and 5C). 
To investigate whether inhibition of Gal-3–regulated 
profibrotic pathways could improve heart function in 
ARVC5, we conducted blinded controlled in vivo ex-
periments in TMEM43mut mice. The mice were treated 
with either saline or GM-CT-01, a galactomannan with 
antifibrotic properties26 that inhibits Gal-3 by binding 
to its carbohydrate-binding domain, which is necessary 
for the formation of Gal-3 pentamers.23 We then ana-
lyzed heart sections for collagen content by Masson 
trichrome staining and type by staining with Picrosirius 
red. Picrosirius red binds specifically to collagen fibrils 
of varying diameters and distinguishes between colla-
gen type I, which confers stiffness to the tissue, and 
collagen type III, which is more elastic. Treatment with 
GM-CT-01 triggered a significant switch in the colla-
gen type in TMEM43mut hearts from collagen type I to 
collagen type III (Figure 5D). Although the sum of the 
collagen fibers seemed to decrease with GM-CT-01, 
the total fibrotic area was not reduced (Figure  5E). 
LVEF was comparable in GM-CT-01–treated and saline-
treated TMEM43mut mice (Figure  5F). These results 
suggest that although collagen in the heart changes 
to a more elastic type, this is not sufficient to restore 
cardiac function.
TMEM43-S358L Causes Cell Death by 
Activating GSK3β
GSK3β is mislocalized and activated in other ARVCs, 
both in patients and in mouse models.18,27 In addition, 
GSK3β inactivation is beneficial in several pathologi-
cal settings, including myocardial infarction28,29 and 
pressure overload.30 To determine whether this sig-
naling pathway was disturbed in ARVC5, we first in-
vestigated whether GSK3β activation was altered by 
TMEM43-S358L. We observed that GSK3β phosphor-
ylation is decreased in TMEM43mut mice compared 
with their WT littermates (Figure 6A and 6B), indicating 
increased GSK3β activation. This was accompanied by 
reduced phosphorylation (indicating decreased activa-
tion) of its upstream regulatory kinase AKT (Figure 6A 
and 6C). To determine whether TMEM43-S358L had 
any effect on β-catenin transcriptional activity, which 
is inhibited by GSK3β we transfected neonatal cardio-
myocytes with an expression vector for the different 
TMEM43 constructs together with a reporter plasmid 
in which luciferase is controlled by several β-catenin–
activated TCF binding sites. We found that human 
TMEM43-S358L decreased β-catenin activation, 
whereas mouse TMEM43-S358L did not (Figure 6D). 
This decrease was prevented by the GSK3β inhibitor 
CHIR99021 (Figure 6E).
Because the AKT pathway is strongly involved in cell 
survival, we investigated the effect of TMEM43-S358L 
on cell viability. Expression of TMEM43-S358L in P19 
cells resulted in increased cell death in the absence of 
growth factors. This effect was precluded by the GSK3β 
inhibitor (Figure  6F). Together, these results indicate 
that TMEM43-S358L expression interferes with the AKT 
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Treatment of TMEM43mut Mice With 
CnAβ1 Prolongs Survival and Improves 
Cardiac Function
CnAβ1, a naturally occurring splice variant of calcineu-
rin Aβ, has a beneficial effect on the heart after inju-
ry.8,31 The distinct properties of CnAβ1 are conferred by 
a unique C-terminal domain, not present in any other 
known protein.32 More important, CnAβ1 is required 
for the activation of the AKT/GSK3β/β-catenin signal-
ing pathway, which results in inhibition of GSK3β and 
activation of β-catenin.33
To determine whether CnAβ1 overexpression could 
revert the activation of GSK3β induced by TMEM43-
S358L, we crossed TMEM43mut mice with mice over-
expressing CnAβ1 in a cardiomyocyte-specific manner.8 
We found that AKT activity was preserved in the hearts 
of double-transgenic mice and that, accordingly, GSK3β 
Figure 5. Inhibition of fibrosis does not improve cardiac function in TMEM43 (transmembrane protein 43) mutant (mut) mice.  
A, Quantitative reverse-transcribed polymerase chain reaction analysis of myocardial galectin-3 (Lgals3) expression in the mouse lines at the indicated  
ages. B and C, Western blot analysis (B) and quantification (C) of Gal-3 (galectin-3) protein levels at different time points in the 3 mouse lines at 4 months 
of age. D, TMEM43mut mice were treated with GM-CT-01 (GM; 120 mg/kg) or saline (Sal), and myocardial sections were stained with Picrosirius red to  
determine the maturity of the collagen fibers in each ventricle. E, The percentage of fibrotic tissue in the hearts of 4-month-old mice was quantified 
by Masson trichrome staining. F, Echocardiography-determined left ventricular (LV) ejection fraction (LVEF) in 5-week-, 2-month-, and 4-month-old 
TMEM43mut mice treated with GM-CT-01 or saline. Graphs show data points for individual mice and mean±SEM. AU indicates arbitrary units; and RV, 
right ventricle. A, ***P<0.001, TMEM43mut vs WT; ###P<0.001, TMEM43mut vs TMEM43WT; $$$P<0.001 for different ages vs neonates for each mouse 
line; n=3 to 8; 2-way regular ANOVA followed by Bonferroni post-test. C, **P<0.01, TMEM43mut vs WT; ##P<0.01, TMEM43mut vs TMEM43WT; 1-way 
ANOVA with Bonferroni correction. D, †††P<0.001, GM-CT-01 vs saline. E and F, ‡‡‡P<0.001 vs 5 weeks; 2-way regular ANOVA followed by Bonferroni 
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was not activated (Figure 6A–6C). In addition, CnAβ1 
restored β-catenin activity (Figure 6E).
Given that CnAβ1 activates AKT and inhibits GSK3β, 
we next investigated whether CnAβ1 overexpression 
improves cardiac function in the double-transgenic 
animals. Most notably, CnAβ1 significantly expanded 
the life span of the mutant mice to a median of 28 
weeks (Figure  6G). Circulating cardiac troponin I lev-
els were significantly reduced at 2 months of age in 
TMEM43mut-CnAβ1 mice (Figure  6H), suggesting a 
partial reduction of cardiomyocyte necrosis in the dou-
ble-transgenic mice. Similarly, chemical inhibition of 
GSK3β with SB-216763 in TMEM43mut mice resulted 
in reduced serum cardiac troponin I, reinforcing the 
idea that GSK3β activation has a causal role in cardio-
myocyte death induced by TMEM43-S358L.
Echocardiography assessment showed significant-
ly superior LV function in TMEM43mut-CnAβ1 mice 
compared with TMEM43mut mice at 4 months of age 
(Figure 7A and Table VI and Video II in the online-only 
Data Supplement). LV dilatation was also reduced in 
double-transgenic animals, although the differences 
Figure 6. TMEM43 (transmembrane protein 43) p.S358L promotes cell death by activating glycogen synthase kinase-3β (GSK3β).  
A through C, TMEM43 mutant (mut) mice were crossed with α-myosin heavy chain–calcineurin Aβ1(CnAβ1) mice overexpressing CnAβ1 in cardiomyocytes 
(TMEM43mut-CnAβ1 mice). The presence of total and phosphorylated (Ser9) GSK3β, as well as total and phosphorylated (Ser473) AKT, was assessed by Western 
blot in myocardial samples from wild-type (WT), TMEM43WT, TMEM43mut, and TMEM43mut-CnAβ1 mice (A) and quantified (B and C). Increased phosphoryla-
tion of GSK3β indicates inactivation; n=3 to 11. D and E, Neonatal mouse cardiomyocytes were transfected with a reporter plasmid in which luciferase expression 
is controlled by a β-catenin–dependent TCF multimer, together with expression plasmids for human (h; D and E) or mouse (m; only in D) WT TMEM43, TMEM43-
S358L, and CnAβ1. Empty pcDNA3.1 was used as a negative control. When indicated, the GSK3β inhibitor CHIR99021 (Chir; 3 μmol/L) was added. F, Percentage 
of viable P19 cells transfected with expression plasmids for human WT TMEM43 and TMEM43-S358L grown in the absence of serum for 32 hours. The GSK3β 
inhibitor CHIR99021 (3 μmol/L) was added when indicated. As a positive control of cell death, P19 cells were incubated with 10% ethanol for 5 hours. G, Sixty-
week Kaplan-Meier survival curves for WT (n=27), TMEM43mut (n=84), and TMEM43mut-CnAβ1 mice (n=38). The indicated P value was obtained with a log-rank 
test. H and I, Serum troponin I (TnI) determined by ELISA in the indicated mice 3 and 5 weeks and 2 and 4 months of age. In I, TMEM43mut mice were treated 
with the GSK3β inhibitor SB-216763 (SB) or dimethyl sulfoxide (DMSO) as a vehicle control; n=4 to 5. Graphs show mean±SEM. B through D and F, *P<0.05, 
**P<0.01, ***P<0.001 vs WT animals or control vector; ##P<0.01, ###P<0.001 vs TMEM43WT. B, δδδP<0.001 vs TMEM43mut; δδP<0.01 CHIR99021-treated 
cells vs untreated. H, **P<0.01, ***P<0.001 vs WT; †††P<0.001, TMEM43mut vs TMEM43mut-CnAβ1. I, ‡‡‡P<0.001, SB vs DMSO. B through F, One-way 
ANOVA followed by Dunnett posttest; n=3 to 11. H and I, Two-way ANOVA followed by Bonferroni posttest; n=10. Note that WT and TMEM43mut mice data for 
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Figure 7. Calcineurin Aβ1 (CnAβ1) overexpression and chemical inhibition of glycogen synthase kinase-3β (GSK3β) improve cardiac function in 
TMEM43 (transmembrane protein 43) mutant (mut) mice.  
A through C, Left ventricular (LV) ejection fraction (EF; A), LV end-diastolic volume (LVEDV; B), and tricuspid annular plane systolic excursion (TAPSE; C) were 
determined by echocardiography in 4-month-old mice. D through F, Surface electrocardiographic determination of p-wave duration (D) and QRS duration and 
amplitude (E and F). G and H, Gross heart morphology (G) and ratio of heart weight to body weight (HW/BW; H) in 4-month-old mice; bar, 500 μm. I, Picrosirius 
red staining analysis of collagen fibers in myocardial sections. J, LVEF was determined by echocardiography in 4-month-old TMEM43mut mice treated with the 
GSK3β inhibitor SB-216763 (SB) or dimethyl sulfoxide (DMSO) as a control. K and L, The p-wave (K) and QRS (L) durations were analyzed by ECG in TMEM43mut 
(Tmut) mice treated as in J. M, Ratio of heart weight to body weight (HW/BW; H) in 4-month-old TMEM43mut mice treated as in J. Graphs in A to F, H and J-M 
show data with mean±SEM. A through F and H, *P<0.05, **P<0.01, ***P<0.001, TMEM43mut or TMEM43-CnAβ1 vs WT; #P<0.05, ###P<0.001, TMEM43mut-
CnAβ1 (Tm-Cn) vs TMEM43mut; 1-way ANOVA followed by Bonferroni posttest; n=6 to 8. I, **P<0.01, ***P<0.001, collagen (Col) type III TMEM43mut vs WT; 
††P<0.01 Col I TMEM43mut-CnAβ1 vs TMEM43mut; ‡‡‡P<0.001, Col III TMEM43-CnAβ1 vs TMEM43mut; 2-way ANOVA followed by Bonferroni posttest; n=3 
to 6. Note that WT and TMEM43mut mice data for A through F and H are those shown in Figures 1B through 1D, 2D through 2F, and 1F and are repeated here 
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with TMEM43mut mice did not reach significance (Fig-
ure 7B). TMEM43mut-CnAβ1 mice also showed a small 
improvement in right ventricular function (tricuspid 
annular plane systolic excursion; Figure  7C) and im-
proved electrocardiographic parameters compared with 
TMEM43mut mice (Figure 7D–7F and Table VII in the 
online-only Data Supplement).
Evaluation of gross heart morphology at 4 months 
showed that TMEM43-CnAβ1 hearts were consider-
ably smaller than those of the TMEM43mut mice (Fig-
ure 7G). In addition, TMEM43-CnAβ1 mice had a sig-
nificantly lower ratio of heart weight to body weight 
than TMEM43mut mice (Figure  7H) and showed no 
evidence of pulmonary congestion (Figure IXA in the 
online-only Data Supplement).
Examination of fibrotic tissue by Masson trichrome 
staining revealed no differences in total collagen con-
tent between TMEM43-CnAβ1 and TMEM43mut 
hearts (Figure IXB and IXC in the online-only Data 
Supplement). However, analysis of fibers by Picrosiri-
us red staining indicated that TMEM43-CnAβ1 mice 
accumulated stiffer fibers (richer in collagen I) than 
TMEM43mut mice (Figure 8I).
In agreement with the beneficial effect of CnAβ1 on 
cardiac function, treatment of TMEM43mut mice with 
the GSK3β inhibitor SB-216763 resulted in improved 
EF and a partial normalization of electric abnormalities 
(Figure  7J–7M). Together, these results demonstrate 
that GSK3β inhibition, either chemically or by CnAβ1 
overexpression, improves cardiac function in mice with 
ARVC5.
Human Induced Pluripotent Stem Cell–
Derived Cardiomyocytes Bearing the 
p.S358L Mutation Show Contraction 
Abnormalities That Are Normalized by 
GSK3β Inhibition
To determine whether the p.S358L mutation induces a 
disease-associated phenotype also in human cells, we 
developed mutant human induced pluripotent stem 
cell (hiPSC)–derived cardiomyocytes (hiPSC-CMs) and 
compared their contraction behavior with that of WT 
cells. No significant differences in Ca2+ transient pa-
rameters were found between phenotypes at baseline 
(Figure 8A–8C). However, in the presence of 1 µmol/L 
isoproterenol, both the rising and decay phases of the 
Ca2+ transient were slower in the mutant phenotype. 
These results were confirmed by measuring hiPSC-CM 
contraction with a recently reported algorithm.34 We 
found significantly increased contraction duration, time 
to peak, and relaxation time in mutant hiPSC-CMs, 
accompanied by decreased contraction amplitude 
(Figure  8D–8G). GSK3β inhibition partially reduced 
contraction time and improved contraction overall (Fig-
ure 8H–8K), reinforcing the idea that GSK3β plays a rel-
evant role in ARVC5.
DISCUSSION
ARVC5 is a devastating disease that causes sudden car-
diac death and heart failure.6 It is caused by a point 
mutation in TMEM43, a transmembrane protein that, 
as shown here, is located in the nuclear membrane in 
its WT form. Despite efforts, this disease remains in-
curable and has no specific therapy. To develop thera-
pies to delay the onset or to slow the progression of 
ARVC5, it is necessary to define the initial molecular 
events and pathophysiological mechanisms. We there-
fore performed a step-by-step characterization of the 
first ARVC5 transgenic mouse line (TMEM43mut) from 
the early stages of the disease to the latest manifesta-
tions of the ACM/ARVC phenotype. TMEM43mut mice 
show biventricular systolic dysfunction as the disease 
progresses and considerable accumulation of fibrofatty 
tissue, thus reproducing the human condition, which 
also shows biventricular affectation in 43% of the cas-
es.7 Unlike other ACM/ARVC mouse models,17,27,35–37 
TMEM43mut hearts accumulate fat in the right ventri-
cle, although to a lower extent than observed in human 
patients, likely as a result of the absence of subepicar-
dial fat in the mouse heart.
The first disease manifestations in TMEM43mut mice 
are electric abnormalities, observed as early as 5 weeks 
of age in ECG. Interestingly, no sudden cardiac death or 
appropriate implantable cardioverter-defibrillator dis-
charge has been reported so far in ARVC5 patients <19 
years of age.38 This corresponds to the onset of the dis-
ease at 5 weeks of age observed in our ARVC5 mouse 
model. Electric features preceded anatomic defects, 
as also described in other ARVC mouse models.39 Al-
though the molecular mechanisms that underlie cellular 
uncoupling and consequent conduction abnormalities 
are poorly understood,40 mislocalization of connexin 43 
that results in gap-junction remodeling would contrib-
ute to defects in impulse propagation and might ex-
plain the early phenotype.17
We show that mutant TMEM43 causes progressive 
cardiomyocyte loss through activation of cell-death 
pathways. Necrosis started early in life, as shown by car-
diac troponin I levels, whereas apoptosis and autoph-
agy appeared only in the later stages of the disease, 
suggesting that necrosis is the main pathway leading 
to early cardiomyocyte death. Sustained cardiomyo-
cyte loss in TMEM43mut hearts progressively led to the 
replacement of dead cells by fibrofatty tissue, eventu-
ally leading to massive interstitial fibrosis in all 4 cham-
bers. We show that epicardium-derived cells contribute 
strongly to cardiac fibrosis in this model, as has also 
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cardial infarction.41 Given that many resident fibroblasts 
in the adult heart are derived from Wt1+ epicardial cells 
during embryonic development, it is likely that the epi-
cardium-derived cells contributing to cardiac fibrosis in 
TMEM43mut mice are resident cardiac fibroblasts. We 
found no contribution from macrophages, endothelial 
cells, or cardiomyocytes, although we cannot rule out 
contributions from other cell types not tested here.
The role of fibrosis in ACM/ARVC is unclear; it could 
represent either a pathological mechanism or a com-
pensatory response. Treating our mouse lines with a 
Gal-3 inhibitor that has antifibrotic properties altered 
the collagen type III/I ratio to a more elastic fiber con-
formation. This, however, had no beneficial effect on 
cardiac function. These results suggest that the fibrotic 
response developed in ARVC5 tries to compensate for 
Figure 8. Human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) bearing the p.TMEM43 (transmembrane protein 43)–S358L 
mutation develop contractile dysfunction.  
A through C, hiPSC-CMs bearing the wild-type (WT) alleles or a heterozygous p.TMEM43-S358L mutation (Mut) were loaded with 5 µmol/L Fluo 4-AM, and Ca2+ 
transients were imaged in individual cells under a confocal microscope in the presence or absence of 1 µmol/L isoproterenol (Iso). D through G, WT and mutant 
hiPSC-CM beating was video recorded, and contraction duration (D), time to peak (E), relaxation time (F), and contraction amplitude (G) were measured. H 
through K, WT and mutant hiPSC-CMs were treated with the glycogen synthase kinase-3β (GSK3β) inhibitor CHIR99021 (GSK3β in.) or dimethyl sulfoxide (DMSO) 
as a control and different contraction parameters were measured. *P<0.05, **P<0.01, ***P<0.001, mutant vs WT cells. ###P<0.001 and adjusted P values in H 
and I refer to GSK3β inhibitor vs DMSO. D through G, Two-sample t test; H through K, regular 2-way ANOVA with Bonferroni posttest; n=10 to 20; (B and C) 46 
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the loss of cardiomyocytes but would not be an appro-
priate therapeutic target.
The Wnt/GSK3β/β-catenin signaling pathway seems 
to play a central role in the pathogenesis of other forms 
of ARVC and is a key regulator of myogenesis.7.GSK3β 
modulates this signaling pathway by phosphorylating 
β-catenin, promoting its rapid turnover by the protea-
some. We show here that TMEM43-S358L inhibits AKT, 
which results in GSK3β activation and inhibition of β-
catenin–dependent transcription. We also show that 
expression of mutant TMEM43 in cell culture causes 
significant cell death in a GSK3-dependent manner, 
demonstrating the functional involvement of GSK3β in 
the deleterious effects of TMEM43-S358L. Although it 
is unclear how it inhibits AKT, we found that TMEM43-
S358L interacts with the AKT modulator Pa2g4 (EBP1 
[Erbb3 interacting protein]). Interaction of Pa2g4 with 
AKT inhibits apoptosis and promotes cell survival.42,43 
Therefore, it is tempting to speculate that by binding 
Pa2g4, TMEM43-S358L interferes with the Pa2g4-AKT 
interaction and thereby reduces the antiapoptotic effect 
of AKT. Overexpression of the calcineurin variant CnAβ1, 
which activates the AKT pathway and inhibits GSK3β, 
significantly expands the life span and improves cardiac 
function in TMEM43mut mice. TMEM43mut-CnAβ1 
mice showed a partial reduction in cardiomyocyte death 
and less severe electric abnormalities, suggesting that 
CnAβ1 overexpression preserves cardiomyocyte func-
tion in the TMEM43mut myocardium. Similarly, chemical 
inhibition of GSK3β reduced cardiomyocyte death and 
electric abnormalities and improved cardiac contraction 
in TMEM43mut mice. The role of GSK3β in the patho-
genesis of ARVC5 was further confirmed in hiPSC-CMs 
bearing the p.S358L mutation, which showed improved 
contraction after GSK3β inhibition.
Our computer models show that the p.S358L point 
mutation in TMEM43 increases the hydrophobicity of 
the molecule and would lead to a distorted protein, 
impairing its function. The dimer formed between 
TMEM43-S358L and the WT form adopts a deformed 
structure that reduces its interaction with other nuclear 
membrane proteins such as EMD, as well as with cyto-
skeleton-interacting proteins. This defective interaction 
is illustrated by the partial delocalization of TMEM43-
S358L to the cytoplasm. The functional implications of 
these protein-protein interactions need to be fully clari-
fied; however, it is plausible that a reduced interaction 
between the nucleus and the cytoskeleton contributes 
to cardiomyocyte death under biomechanical stress.
Interestingly, our computer models also showed that 
the third transmembrane domain in mouse TMEM43 
has a different conformation and orientation from that 
of the human protein. More important, the p.S358L 
mutation has no effect on the structure of mouse 
TMEM43. The lack of a structural change in the mu-
tant mouse protein is likely the reason why it does not 
inhibit β-catenin signaling and why knock-in mice bear-
ing the p.S358L mutation have no pathological phe-
notype.14 In addition, by using a cardiomyocyte-specific 
promoter to express TMEM43-S358L, we can conclude 
that ARVC5 is originated in cardiomyocytes and not in 
other cell types.
We show that human TMEM43-S358L causes cardio-
myocyte death and fibrofatty replacement. Although 
it appears that fibrosis is not an effective therapeutic 
target, GSK3β inhibition by CnAβ1 overexpression or a 
chemical inhibitor has a beneficial effect on the mutant 
hearts. It will be interesting to explore GSK3β inhibitors 
as potential therapeutic agents for ARVC5 to improve 
the life of patients with this incurable disease.
Limitations
Although our transgenic mouse is the only model that 
reproduces human ARVC5, certain characteristics of 
the human disease were not presented by this model. 
No significant differences were found between males 
and females, in contrast to human patients. In addition, 
mice show fat infiltration in the myocardium but not to 
the extent found in ARVC5 human hearts.
ARTICLE INFORMATION
Received February 19, 2019; accepted July 3, 2019.
The online-only Data Supplement is available with this article at https://
www.ahajournals.org/doi/suppl/10.1161/circulationaha.119.040366.
Correspondence
Enrique Lara-Pezzi, PhD, Myocardial Pathophysiology Area, Centro Nacional 
de Investigaciones Cardiovasculares Carlos III, Melchor Fernandez Almagro, 3, 
28029 Madrid, Spain; or Pablo Garcia-Pavia, MD, PhD, Inherited Cardiac Dis-
eases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro, 
Manuel de Falla, 2. Majadahonda, Madrid, 28222, Spain. Email elara@cnic.es 
or pablogpavia@yahoo.es
Affiliations
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, 
Spain (L.P.-B., M.V.-O., J.M.G.-S., F.D., J.L.-A., P.O.-S., F.M., M.L.-O., E.B.-K., 
J.V., C.M.-G., D.J.S., B.P., G.G., S.P., E.L.-P.). Heart Failure and Inherited Car-
diac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de 
Hierro Majadahonda, Madrid, Spain (L.P.-B., F.D., M.R., P.G.-P.). CIBER Cardio-
vascular Diseases (CIBERCV), Madrid, Spain (L.P.-B., F.D., E.B.-K., J.V., C.M.-G., 
P.G.-P., E.L.-P.). ERN GUARD-HEART (European Reference Network for Rare and 
Complex Diseases of the Heart) (F.D., S.P., P.G.-P.). Departamento de Medicina 
y Cirugía Experimental, Instituto de Investigación Sanitaria Gregorio Marañón, 
Madrid, Spain (M.V.G.-G.). Centro de Investigación Biomédica en Red de Salud 
Mental (CIBERSAM), Madrid, Spain (M.V.G.-G.). Molecular Cardiology, IRCCS 
Istituti Clinici Scientifici Maugeri, Pavia, Italy (S.P.). Facultad de Ciencias de la 
Salud, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain 
(P.G.-P.). Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Madrid, 
Spain (P.G.-P.).  Faculty of Medicine, National Heart & Lung Institute, Imperial 
College London, UK (E.L.-P.).
Acknowledgments
The authors thank F. Montoya for mouse work, E. Arza and V. Labrador from 
the Centro Nacional de Investigaciones Cardiovasculares Carlos III Microscopy 
Unit for help with microscopy, R. Doohan for immunostaining advice, J.A. Ber-




 http://ahajournals.org by on O
ctober 22, 2019
Padrón-Barthe et al TMEM43 and ARVC5
Circulation. 2019;140:1188–1204. DOI: 10.1161/CIRCULATIONAHA.119.040366 October 1, 2019 1203
ORIGINAL RESEARCH 
ARTICLE
the Gal3 inhibitor treatment, and S. Bartlett for English editing. RNA sequenc-
ing experiments were performed in the Centro Nacional de Investigaciones 
Cardiovasculares Carlos III Genomics Unit and analyzed by the Bioinformatics 
Unit. Anti-TMEM43 was a kind gift of Dr Franke Werner (DKFZ, Heidelberg, 
Germany). Conceptualization: E.L.-P., P.G.-P., and L.P.-B.; methodology: L.P.-
B., M.V.-O., J.G.-S., P.O.-S., C.M.-G., F.M., D.J.S., B.P., G.G., E.B.-K., J.V., and 
M.V.G.-G.; investigation: L.P.-B., M.V.-O., J.G.-S., M.R., J.L.-A., P.O.-S., C.M.-G., 
F.M., M.L.-O., E.B.-K., J.V., D.J.S, B.P., G.G., S.P., F.D., and M.V.G.-G.; formal 
analysis: L.P.-B., M.V.-O., E.B.-K., J.V., F.M., M.V.G.-G., C.M.-G., S.P., D.J.S., P.G.-
P., and E.L.-P.; writing, original draft: L.P.-B., E.L.-P., and P.G-P.; writing, review 
and editing: L.P.-B., E.L.-P., and P.G-P.; funding acquisition: E.L.-P. and P.G.-P.; 
supervision, E.L.-P. and P.G.-P.; and project administration, E.L.-P. and P.G.-P.
Sources of Funding
This work was supported by grants from the European Union (CardioNeT-
ITN-289600 and CardioNext-608027 to Dr Lara-Pezzi), the Spanish Ministry 
of Economy and Competitiveness (RTI2018-096961-B-I00, SAF2015-65722-R, 
and SAF2012-31451 to Dr Lara-Pezzi; SAF2015-71863-REDT to Dr Garcia-
Pavia), the Spanish Carlos III Institute of Health (PI14/0967 to Dr Garcia-Pavia, 
CPII14/00027 to Dr Lara-Pezzi; RD012/0042/0066 to Drs Garcia-Pavia and Lara-
Pezzi), the Regional Government of Madrid (2010-BMD-2321 “Fibroteam” to 
Dr Lara-Pezzi), the Isabel Gemio Foundation (Todos somos Raros grant to Dr 
Garcia-Pavia), and the Spanish Society of Cardiology (2014 Basic Research Grant 
to Dr Garcia-Pavia). This work was also supported by the Plan Estatal de I+D+I 
2013-2016–European Regional Development Fund (FEDER) “A way of mak-
ing Europe,” Spain. The Centro Nacional de Investigaciones Cardiovasculares 
Carlos III is supported by the Ministerio de Ciencia, Innovación y Universidades 
(MCNU), and Pro Centro Nacional de Investigaciones Cardiovasculares Carlos 




 1. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardio-
myopathy. N Engl J Med. 2017;376:61–72. doi: 10.1056/NEJMra1509267
 2. Stadiotti I, Catto V, Casella M, Tondo C, Pompilio G, Sommariva E. Ar-
rhythmogenic cardiomyopathy: the guilty party in adipogenesis. J Cardio-
vasc Transl Res. 2017;10:446–454. doi: 10.1007/s12265-017-9767-8
 3. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, 
Tedford RJ, Judge DP, Calkins H. Exercise increases age-related penetrance 
and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardio-
myopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 
2013;62:1290–1297. doi: 10.1016/j.jacc.2013.06.033
 4. Padrón-Barthe L, Domnguez F, Garcia-Pavia P, Lara-Pezzi E. Animal mod-
els of arrhythmogenic right ventricular cardiomyopathy: what have we 
learned and where do we go? Insight for therapeutics. Basic Res. Cardiol. 
2017;112:50-56.
 5. Ye L, Ni X, Zhao ZA, Lei W, Hu S. The application of induced pluripo-
tent stem cells in cardiac disease modeling and drug testing. J Cardiovasc 
Transl Res. 2018;11:366–374. doi: 10.1007/s12265-018-9811-3
 6. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French  
VM, Drenckhahn JD, Kupprion C, Ramadanova K, Thierfelder L, McKenna 
W, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a 
fully penetrant, lethal arrhythmic disorder caused by a missense muta-
tion in the TMEM43 gene. Am J Hum Genet. 2008;82:809–821. doi: 
10.1016/j.ajhg.2008.01.010
 7. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young TL, 
McKenna WJ, Gallagher B, Curtis F, Bassett AS, Parfrey PS. The natural 
history of a genetic subtype of arrhythmogenic right ventricular car-
diomyopathy caused by a p.S358L mutation in TMEM43. Clin Genet. 
2013;83:321–331. doi: 10.1111/j.1399-0004.2012.01919.x
 8. Felkin LE, Narita T, Germack R, Shintani Y, Takahashi K, Sarathchandra P, 
López-Olañeta MM, Gómez-Salinero JM, Suzuki K, Barton PJ, et al. Calcineu-
rin splicing variant calcineurin Aβ1 improves cardiac function after myocar-
dial infarction without inducing hypertrophy. Circulation. 2011;123:2838–
2847. doi: 10.1161/CIRCULATIONAHA.110.012211
 9. Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández  
D, Vázquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, 
Mittelbrunn M, Sánchez-Madrid F. Sumoylated hnRNPA2B1 controls the 
sorting of miRNAs into exosomes through binding to specific motifs. Nat 
Commun. 2013;4:2980. doi: 10.1038/ncomms3980
 10. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, 
Calkins H, Corrado D, Cox MG, Daubert JP, et al. Diagnosis of arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia: proposed modifi-
cation of the task force criteria. Circulation. 2010;121:1533–1541. doi: 
10.1161/CIRCULATIONAHA.108.840827
 11. Lavandero S, Chiong M, Rothermel BA, Hill JA. Autophagy in cardiovascu-
lar biology. J Clin Invest. 2015;125:55–64. doi: 10.1172/JCI73943
 12. Dreger M, Bengtsson L, Schöneberg T, Otto H, Hucho F. Nuclear enve-
lope proteomics: novel integral membrane proteins of the inner nucle-
ar membrane. Proc Natl Acad Sci U S A. 2001;98:11943–11948. doi: 
10.1073/pnas.211201898
 13. Bengtsson L, Otto H. LUMA interacts with emerin and influences its dis-
tribution at the inner nuclear membrane. J Cell Sci. 2008;121(pt 4):536–
548. doi: 10.1242/jcs.019281
 14. Franke WW, Dörflinger Y, Kuhn C, Zimbelmann R, Winter-Simanowski S, 
Frey N, Heid H. Protein LUMA is a cytoplasmic plaque constituent of vari-
ous epithelial adherens junctions and composite junctions of myocardial 
intercalated disks: a unifying finding for cell biology and cardiology. Cell 
Tissue Res. 2014;357:159–172. doi: 10.1007/s00441-014-1865-1
 15. Liang WC, Mitsuhashi H, Keduka E, Nonaka I, Noguchi S, Nishino I, 
Hayashi YK. TMEM43 mutations in Emery-Dreifuss muscular dystrophy-re-
lated myopathy. Ann Neurol. 2011;69:1005–1013. doi: 10.1002/ana.22338
 16. Stroud MJ, Fang X, Zhang J, Guimarães-Camboa N, Veevers J, Dalton ND, 
Gu Y, Bradford WH, Peterson KL, Evans SM, et al. Luma is not essential for 
murine cardiac development and function. Cardiovasc Res. 2018;114:378–
388. doi: 10.1093/cvr/cvx205
 17. Lyon RC, Mezzano V, Wright AT, Pfeiffer E, Chuang J, Banares K, 
Castaneda A, Ouyang K, Cui L, Contu R, et al. Connexin defects underlie 
arrhythmogenic right ventricular cardiomyopathy in a novel mouse model. 
Hum Mol Genet. 2014;23:1134–1150. doi: 10.1093/hmg/ddt508
 18. Chelko SP, Asimaki A, Andersen P, Bedja D, Amat-Alarcon N, 
DeMazumder D, Jasti R, MacRae CA, Leber R, Kleber AG, et al. Central 
role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy. 
JCI Insight. 2016;1:e85923.
 19. Schirmer EC, Florens L, Guan T, Yates JR 3rd, Gerace L. Nuclear membrane 
proteins with potential disease links found by subtractive proteomics. Sci-
ence. 2003;301:1380–1382. doi: 10.1126/science.1088176
 20. Dreger M, Bengtsson L, Schöneberg T, Otto H, Hucho F. Nuclear enve-
lope proteomics: novel integral membrane proteins of the inner nucle-
ar membrane. Proc Natl Acad Sci U S A. 2001;98:11943–11948. doi: 
10.1073/pnas.211201898
 21. Rajkumar R, Sembrat JC, McDonough B, Seidman CE, Ahmad F. Func-
tional effects of the TMEM43 Ser358Leu mutation in the pathogenesis 
of arrhythmogenic right ventricular cardiomyopathy. BMC Med Genet. 
2012;13:21. doi: 10.1186/1471-2350-13-21
 22. van Spreeuwel ACC, Bax NAM, van Nierop BJ, Aartsma-Rus A, 
Goumans MTH, Bouten CVC. Mimicking cardiac fibrosis in a dish: fibroblast 
density rather than collagen density weakens cardiomyocyte function. J Car-
diovasc Transl Res. 2017;10:116–127. doi: 10.1007/s12265-017-9737-1
 23. Traber PG, Zomer E. Therapy of experimental NASH and fibro-
sis with galectin inhibitors. PLoS One. 2013;8:e83481. doi: 
10.1371/journal.pone.0083481
 24. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, 
van der Harst P, Pitt B, Goldstein IJ, Koerts JA, et al. Genetic and pharma-
cological inhibition of galectin-3 prevents cardiac remodeling by interfer-
ing with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107–117. doi: 
10.1161/CIRCHEARTFAILURE.112.971168
 25. Takemoto Y, Ramirez RJ, Yokokawa M, Kaur K, Ponce-Balbuena D, 
Sinno MC, Willis BC, Ghanbari H, Ennis SR, Guerrero-Serna G, et al. Ga-
lectin-3 regulates atrial fibrillation remodeling and predicts catheter abla-
tion outcomes. JACC Basic Transl. Sci. 2016;1:143–154.
 26. Ahmad N, Gabius HJ, André S, Kaltner H, Sabesan S, Roy R, Liu B, Macaluso F, 
Brewer CF. Galectin-3 precipitates as a pentamer with synthetic multiva-
lent carbohydrates and forms heterogeneous cross-linked complexes. J 
Biol Chem. 2004;279:10841–10847. doi: 10.1074/jbc.M312834200
 27. Martherus R, Jain R, Takagi K, Mendsaikhan U, Turdi S, Osinska H, 
James JF, Kramer K, Purevjav E, Towbin JA. Accelerated cardiac remodel-
ing in desmoplakin transgenic mice in response to endurance exercise is 
associated with perturbed Wnt/β-catenin signaling. Am J Physiol Heart 
Circ Physiol. 2016;310:H174–H187. doi: 10.1152/ajpheart.00295.2015
 28. Woulfe KC, Gao E, Lal H, Harris D, Fan Q, Vagnozzi R, DeCaul M, 




 http://ahajournals.org by on O
ctober 22, 2019
Padrón-Barthe et al TMEM43 and ARVC5














regulates post-myocardial infarction remodeling and stress-induced car-
diomyocyte proliferation in vivo. Circ Res. 2010;106:1635–1645. doi: 
10.1161/CIRCRESAHA.109.211482
 29. Miura T, Tanno M. Mitochondria and GSK-3beta in cardioprotection 
against ischemia/reperfusion injury. Cardiovasc Drugs Ther. 2010;24:255–
263. doi: 10.1007/s10557-010-6234-z
 30. Matsuda T, Zhai P, Maejima Y, Hong C, Gao S, Tian B, Goto K, Takagi H, 
Tamamori-Adachi M, Kitajima S, et al. Distinct roles of GSK-3alpha and 
GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl 
Acad Sci U S  A. 2008;105:20900–20905. doi: 10.1073/pnas.0808315106
 31. López-Olañeta MM, Villalba M, Gómez-Salinero JM, Jiménez-Borreguero LJ, 
Breckenridge R, Ortiz-Sánchez P, García-Pavía P, Ibáñez B, Lara-Pezzi E. 
Induction of the calcineurin variant CnAβ1 after myocardial infarction re-
duces post-infarction ventricular remodelling by promoting infarct vascu-
larization. Cardiovasc Res. 2014;102:396–406. doi: 10.1093/cvr/cvu068
 32. Lara-Pezzi E, Winn N, Paul A, McCullagh K, Slominsky E, Santini MP, 
Mourkioti F, Sarathchandra P, Fukushima S, Suzuki K, et al. A naturally oc-
curring calcineurin variant inhibits FoxO activity and enhances skeletal muscle 
regeneration. J Cell Biol. 2007;179:1205–1218. doi: 10.1083/jcb.200704179
 33. Gómez-Salinero JM, 
López-Olañeta MM, Ortiz-Sánchez P, Larrasa-Alonso J, Gatto A, Felkin LE, 
Barton PJR, Navarro-Lérida I, Ángel Del Pozo M, García-Pavía P, et al. The 
calcineurin variant CnAβ1 controls mouse embryonic stem cell differen-
tiation by directing mTORC2 membrane localization and activation. Cell 
Chem Biol. 2016;23:1372–1382. doi: 10.1016/j.chembiol.2016.09.010
 34. Sala L, van Meer BJ, Tertoolen LGJ, Bakkers J, Bellin M, Davis RP, 
Denning C, Dieben MAE, Eschenhagen T, Giacomelli E, et al. MUSCLEMO-
TION: a versatile open software tool to quantify cardiomyocyte and car-
diac muscle contraction in vitro and in vivo. Circ Res. 2018;122:e5–e16. 
doi: 10.1161/CIRCRESAHA.117.312067
 35. Pilichou K, Remme CA, Basso C, Campian ME, Rizzo S, Barnett P, 
Scicluna BP, Bauce B, van den Hoff MJ, de Bakker JM, et al. Myocyte 
necrosis underlies progressive myocardial dystrophy in mouse dsg2-
related arrhythmogenic right ventricular cardiomyopathy. J Exp Med. 
2009;206:1787–1802. doi: 10.1084/jem.20090641
 36. Kant S, Krull P, Eisner S, Leube RE, Krusche CA. Histological and ultrastruc-
tural abnormalities in murine desmoglein 2-mutant hearts. Cell Tissue Res. 
2012;348:249–259. doi: 10.1007/s00441-011-1322-3
 37. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, 
Khoury DS, Marian AJ. Suppression of canonical Wnt/beta-catenin sig-
naling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic 
right ventricular cardiomyopathy. J Clin Invest. 2006;116:2012–2021. doi: 
10.1172/JCI27751
 38. Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young T-L, 
Curtis F, Collier A, Parfrey PS, Connors SP. Long-term clinical outcome 
of arrhythmogenic right ventricular cardiomyopathy in individuals with 
a p.S358L mutation in TMEM43 following implantable cardioverter de-
fibrillator therapy. Circ Arrhythm Electrophysiol. 2016;9:e003589. doi: 
10.1161/CIRCEP.115.003589
 39. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Saffitz JE, 
Quarta G, Nobles M, Syrris P, Chaubey S, et al. Electrophysiological ab-
normalities precede overt structural changes in arrhythmogenic right ven-
tricular cardiomyopathy due to mutations in desmoplakin-A combined 
murine and human study. Eur Heart J. 2012;33:1942–1953. doi: 
10.1093/eurheartj/ehr472
 40. Li J, Patel VV, Kostetskii I, Xiong Y, Chu AF, Jacobson JT, Yu C, Morley GE, 
Molkentin JD, Radice GL. Cardiac-specific loss of n-cadherin leads to al-
teration in connexins with conduction slowing and arrhythmogenesis. Circ 
Res. 2005;97:474–481.
 41. Smart N, Bollini S, Dubé KN, Vieira JM, Zhou B, Davidson S, Yellon D, 
Riegler J, Price AN, Lythgoe MF, et al. De novo cardiomyocytes from within 
the activated adult heart after injury. Nature. 2011;474:640–644. doi: 
10.1038/nature10188
 42. Liu Z, Ahn JY, Liu X, Ye K. Ebp1 isoforms distinctively regulate cell survival 
and differentiation. Proc Natl Acad Sci U S A. 2006;103:10917–10922. 
doi: 10.1073/pnas.0602923103
 43. Ahn JY, Liu X, Liu Z, Pereira L, Cheng D, Peng J, Wade PA, Hamburger AW, 
Ye K. Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing 





 http://ahajournals.org by on O
ctober 22, 2019
